000 01853cam  2200361zi 4500
0019.898655
003CaOODSP
00520240724144713
006m     o  d f      
007cr |||||||||||
008210413t20212019onc     ob   f00| 0 eng d
020 |a9780660384337
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP40-286/2021E-PDF
24500|aUse of measles-mumps-rubella (MMR) vaccine for the management of mumps outbreaks in Canada.
250 |a[July 2021 edition].
264 1|a[Ottawa] : |bPublic Health Agency of Canada = Agence de la santé publique du Canada,|c2021.
264 4|c©2019
300 |a1 online resource (50 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Utilisation du vaccin contre la rougeole, la rubéole et les oreillons (RRO) pour la prise en charge des éclosions d’oreillons au Canada.
500 |aAt head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI).
500 |a"Publication date: July 2021."
504 |aIncludes bibliographical references (pages 33-39).
650 0|aMumps|xVaccination|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
7101 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body.
77508|tUtilisation du vaccin contre la rougeole, la rubéole et les oreillons (RRO) pour la prise en charge des éclosions d’oreillons au Canada. |w(CaOODSP)9.898656
794 |tUse of measles-mumps-rubella (MMR) vaccine for the management of mumps outbreaks in Canada.|b[Revised 2024 edition]|w(CaOODSP)9.937672
85640|qPDF|s693 KB|uhttps://publications.gc.ca/collections/collection_2021/aspc-phac/HP40-286-2021-eng.pdf